Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron rep
|Shares Outstanding||EPS||1.11||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||385.93%||Sales Growth - Q/Q||38.41%||P/E||14.77|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||11.63%||ROE||26.74%||ROI||15.98%|
|Current Ratio||1.71||Quick Ratio||1.61||Long Term Debt/Equity||1.51||Debt Ratio||0.45|
|Gross Margin||81.03%||Operating Margin||31.1%||Net Profit Margin||65.25%||Dividend Payout Ratio|
|Cash From Financing Activities||183.64 M||Cash From Investing Activities||-284.74 M||Cash From Operating Activities||71.69 M||Gross Profit||104.2 M|
|Net Profit||33.26 M||Operating Profit||61.12 M||Total Assets||1.64 B||Total Current Assets||555.48 M|
|Total Current Liabilities||323.97 M||Total Debt||483.2 M||Total Liabilities||926.3 M||Total Revenue||123.88 M|
|High 52 week||25.65||Low 52 week||10.34||Last close||10.34||Last change||-4.08%|
|RSI||40.26||Average true range||0.72||Beta||0.76||Volume||768.3 K|
|Simple moving average 20 days||-8.89%||Simple moving average 50 days||-14.38%||Simple moving average 200 days||-41.9%|
|Performance Week||-10.32%||Performance Month||-13.18%||Performance Quart||-38.12%||Performance Half||-56.92%|
|Performance Year||-21.96%||Performance Year-to-date||-31.93%||Volatility daily||4.01%||Volatility weekly||8.97%|
|Volatility monthly||18.39%||Volatility yearly||63.7%||Relative Volume||235.39%||Average Volume||747.72 K|
|New High||New Low|
2019-06-25 15:49:00 | Why Palatin Technologies Stock Dropped as Much as 21.5% Today
2019-06-24 17:45:09 | AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire
2019-06-24 16:19:00 | Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
2019-06-24 13:58:00 | Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.
2019-06-24 08:03:00 | Palatin's stock rockets after FDA OK to market sexual desire disorder treatment
2019-06-22 15:07:43 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
2019-06-21 17:41:00 | AMAG stock rallies on FDA approval for drug to increase women's sex drive
2019-06-21 17:37:37 | Amag’s plan to bypass female libido drug pitfalls? Social media.
2019-06-20 09:00:01 | All You Need to Know About AMAG Pharmaceuticals AMAG Rating Upgrade to Buy
2019-06-10 09:39:01 | TherapeuticsMD Enters Agreement to Market Drugs Outside US
2019-06-06 09:31:01 | AMAG Pharmaceuticals AMAG Down 8.9% Since Last Earnings Report: Can It Rebound?
2019-06-05 15:45:00 | AMAG Pharmaceuticals Could Be Cut in Half Even From Here - Avoid
2019-05-29 08:00:00 | AMAG Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
2019-05-20 15:15:07 | Is AMAG Pharmaceuticals, Inc.'s NASDAQ:AMAG Balance Sheet A Threat To Its Future?
2019-05-20 05:21:09 | New Strong Sell Stocks for May 20th
2019-05-17 08:00:00 | AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York
2019-05-10 10:31:02 | New Strong Sell Stocks for May 10th
2019-05-09 19:48:52 | Is AMAG Pharmaceuticals, Inc. AMAG A Good Stock To Buy?
2019-05-09 19:15:01 | Amag Pharmaceuticals Inc AMAG President & CEO William K Heiden Bought $107,000 of Shares
2019-05-09 06:57:10 | AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates
2019-05-08 08:30:03 | Edited Transcript of AMAG earnings conference call or presentation 7-May-19 12:00pm GMT
2019-05-07 13:23:24 | AMAG Pharmaceuticals Inc AMAG Q1 2019 Earnings Call Transcript
2019-05-07 08:35:12 | AMAG Pharmaceuticals AMAG Reports Q1 Loss, Lags Revenue Estimates
2019-05-07 07:28:34 | AMAG Pharmaceuticals: 1Q Earnings Snapshot
2019-04-12 08:00:00 | AMAG Pharmaceuticals Appoints New Members to Board of Directors
2019-04-02 08:00:00 | AMAG Pharmaceuticals to Present at Needham 18th Annual Healthcare Conference
2019-03-18 12:43:33 | New Doubt on Treatment to Prevent Preterm Birth
2019-03-13 10:46:02 | Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
2019-03-09 09:31:02 | Why Is AMAG Pharmaceuticals AMAG Down 24.5% Since Last Earnings Report?
2019-03-08 11:26:41 | Amag's shares fall after $323M pregnancy drug fails in post-approval trial
2019-03-05 08:00:00 | AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
2019-03-01 15:48:25 | AMAG Pharmaceuticals Inc AMAG Files 10-K for the Fiscal Year Ended on December 31, 2018
2019-02-28 12:31:49 | Antares Pharma Inc ATRS Q4 2018 Earnings Conference Call Transcript
2019-02-19 08:00:00 | AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference
2019-02-08 20:59:18 | AMAG Pharmaceuticals AMAG Q4 2018 Earnings Conference Call Transcript